Literature DB >> 12065796

Small cell lung cancer: current therapy and promising new regimens.

Scott H Okuno1, James R Jett.   

Abstract

In this review, we cover current therapy and promising new regimens and highlight areas where improvement is needed in the management of small cell lung cancer.

Entities:  

Mesh：

Year:  2002        PMID： 12065796     DOI： 10.1634/theoncologist.7-3-234

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


  7 in total

1.  Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis.

Authors:  T Korkmaz; S Seber; U Kefeli; E Sari; M Canhoroz; B Oven; E Yildirim; N Yasar; D Aydin; O Balvan; N Sener; S Yuksel; A Mert; O Polat; F Yumuk; O Kanat; M Gumus; N S Turhal
Journal:  Clin Transl Oncol       Date:  2012-11-10       Impact factor: 3.405

2.  A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer.

Authors:  Jennifer Garst; James E Herndon; Timothy Shafman; Lara Campagna; Susan Blackwell; Karen Padilla; Toni Bjurstrom; Carolyn Andrews; Diana Maravich-May; Elizabeth Anderson; Jeffrey Crawford
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

Review 3.  Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Small Cell Lung Cancer.

Authors:  Barbara Melosky; Parneet K Cheema; Anthony Brade; Deanna McLeod; Geoffrey Liu; Paul Wheatley Price; Kevin Jao; Devin D Schellenberg; Rosalyn Juergens; Natasha Leighl; Quincy Chu
Journal:  Oncologist       Date:  2020-09-23

4.  Small cell neuroendocrine tumor of the breast in a 40 year-old woman: a case report.

Authors:  Stefania Nicoletti; Maximilian Papi; Fabrizio Drudi; Manuela Fantini; Debora Canuti; Emiliano Tamburini; Cinzia Possenti; Enzo Pasquini; Massimo Brisigotti; Alberto Ravaioli
Journal:  J Med Case Rep       Date:  2010-06-30

5.  Topotecan: An evolving option in the treatment of relapsed small cell lung cancer.

Authors:  Jennifer Garst
Journal:  Ther Clin Risk Manag       Date:  2007-12       Impact factor: 2.423

6.  RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets.

Authors:  Corey A Carter; Bryan T Oronsky; Scott Z Caroen; Jan J Scicinski; Aiste Degesys; Michelle M Kim; Arnold L Oronsky; Harry Lybeck; Pedro Cabrales; Neil Oronsky; Tony Reid; Joseph Roswarski; Christina Brzezniak
Journal:  Case Rep Oncol       Date:  2016-03-11

7.  The Impact of Serum Glucose, Anti-Diabetic Agents, and Statin Usage in Non-small Cell Lung Cancer Patients Treated With Definitive Chemoradiation.

Authors:  Nick A Iarrobino; Beant S Gill; Mark Bernard; Rainer J Klement; Maria Werner-Wasik; Colin E Champ
Journal:  Front Oncol       Date:  2018-07-27       Impact factor: 6.244
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.